Eventos adversos del nimotuzumab en pacientes con tumor cerebral primario / Adverse events to the nimotuzumab in patients with primary cerebral tumor
Medisan
; 26(1)feb. 2022. tab
Article
em Es
| LILACS, CUMED
| ID: biblio-1405766
Biblioteca responsável:
CU418.1
RESUMEN
Introducción:
El nimotuzumab es un anticuerpo monoclonal empleado en el tratamiento de pacientes con tumor cerebral. Dada su novedad se justifica la realización de estudios de farmacovigilancia que avalen su seguridad.Objetivo:
Caracterizar los eventos adversos relacionados con este medicamento en la práctica médica habitual.Métodos:
Se realizó un estudio descriptivo y transversal de 41 pacientes con tumor cerebral primario tratados con nimotuzumab en el Departamento de Ensayos Clínicos del Hospital Provincial Docente Saturnino Lora Torres de Santiago de Cuba, desde mayo de 2017 hasta abril de 2019.Resultados:
En la serie se identificaron 31 eventos adversos, de los cuales 17 eran conocidos y 14 desconocidos. Predominaron la cefalea (80,5 %), la debilidad en miembros inferiores (48,8 %) y la fosfatasa alcalina elevada (41,5 %). Cabe destacar que el total de los efectos no deseados se consideraron ligeros, según su intensidad; reversibles, según sus resultados y sin cambios, según la actitud respecto al medicamento.Conclusiones:
Las características de los eventos adversos encontrados se asemejan a las descritas en otros estudios que también avalan la seguridad del fármaco.ABSTRACT
Introduction:
The nimotuzumab is a monoclonal antibody used in the treatment of patients with cerebral tumor. The realization of pharmaco surveillance studies that guaranteed its security is justified given its new features.Objective:
To characterize the adverse events related to this medicine in the habitual medical practice.Methods:
A descriptive and cross-sectional study of 41 patients with primary cerebral tumor treated with nimotuzumab in the Clinical Trial Department of Saturnino Lora Torres Teaching Provincial Hospital was carried out in Santiago de Cuba, from May, 2017 to April, 2019.Results:
In the series 31 adverse events were identified, of which 17 were known and 14 were unknown. There was a prevalence of the headache (80.5 %), weakness in lower members (48.8 %) and the high alcaline phosphatase (41.5 %). It is necessary to highlight that all the non wanted effects were considered light according to the intensity; reversible, according to the results and without changes, according to the attitude regarding the medicine.Conclusions:
The characteristics of the adverse events that were found resemble to those described in other studies that also guarantee the security of the drug.Palavras-chave
Texto completo:
1
Base de dados:
CUMED
/
LILACS
Assunto principal:
Neoplasias Encefálicas
/
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos
/
Anticorpos Monoclonais
Tipo de estudo:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Idioma:
Es
Ano de publicação:
2022
Tipo de documento:
Article